Podcasts
-
IP Discussion with Vera Nackovic of Mayer Brown (Part 2 of 2)
BioUtah President & CEO Kelvyn Cullimore interviews Vera Nackovic, patent attorney for Mayer Brown, in the second of…
-
IP Discussion with Vera Nackovic of Mayer Brown (Part 1 of 2)
BioUtah President & CEO Kelvyn Cullimore interviews Vera Nackovic, patent attorney for Mayer Brown, in the first of…
-
Wilson Sonsini
BioUtah president & CEO Kelvyn Cullimore interviews Wilson Sonisini attorneys Meredith Krannich and Deno Himonas to discuss…
-
James McCullough, Renalytix
BioUtah president & CEO Kelvyn Cullimore interviews Renalytix CEO James McCullough to discuss the growth, innovations of Renalytix,…
-
George O’Brien of Mayer Brown
BioUtah president & CEO Kelvyn Cullimore interviews Mayer Brown’s George O’Brien to legal issues life sciences companies face…
-
James McCullough of RenalytixAI
BioUtah president & CEO Kelvyn Cullimore interviews RenalytixAI CEO James McCullough to discuss the growth and innovations of…
-
Brad Brown of ATL Technology
With a manufacturing facility in China, Utah-based ATL Technology was faced to deal with COVID months before the…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
